News

A smartwatch and patch product from Biobeat will allow physicians and patients to monitor blood pressure, oxygenation, and heart rates in both inpatient and outpatient settings.

The new approval represents the third time the FDA approved the injection treatments for adults.

A review of 11 websites found that information available online to patients varies greatly in terms of quality, accuracy, and readability.

A recent study from South Korea is shedding light on the association of blood pressure levels and cardiorenal events.

A study from ESC 2019 found the occurrence of ACS was more common in winter months and heavily polluted cities after examining more than 15,000 patients from across Poland.

What is the large-scale study looking to bring to clinical respiratory health understanding?

The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.

In what ways do the respiratory conditions differentiate in progression and care options?

As part of the Parkinson’s Progression Markers Initiative, researchers announce the addition of RNA sequencing dataset.

A 600-city analysis of particulate matter found daily exposure is linked to worsened mortality rates, particularly in areas with higher mean temperatures.

How does the highly recommended practice benefit patients, and where are its gaps in care?

A new set of guidelines has been released by the American College of Rheumatology, Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network are offering guidance to physicians on treating axial spondyloarthritis.

New data suggests that type 2 diabetes linked to PTSD are less likely to occur among patients with clinically meaningful PTSD symptom reduction through treatment or spontaneous improvement.

Results of the PolyIran study, which examined more than 6000 patients, found that use of a polypill reduced the risk of major cardiovascular events.

National Institute of Health Research study found that physicial activity, even for just 24 minutes per day, was associated with reduced risk of all-cause mortality.

The OneDraw A1C Test System was granted marketing clearance based on the strength of clinical findings reported at ADA 2019.

World Health Organization review finds that consumption of fish oil supplements have little to no impact on development or diagnosis of diabetes.

In a comprehensive new study, investigators discover unique patterns in the brains of both family members and patients with psychotic disorders, including bipolar disorder and schizophrenia.

How do physicians help manage their patient's sleep health for best outcomes?

A recent analysis of the Asian Sudden Cardiac Death in Heart Failure registry found that type 2 diabetes mellitus was associated with structural changes of the heart and poorer quality of life.

A pattern of poor sleep could lead to worsened psychiatric wellbeing—and eventually, memory loss.

In a new study, investigators examine the efficacy and tolerability of antipsychotic medications for patients in remission for psychotic depression.

In a new population-based study, investigators discover sex differences in burdensome interventions and antibiotic therapy for nursing home residents with advanced dementia in Canada.

Findings from the Insight 46 study reveal blood pressure changes during midlife can lead to poorer brain health as a patient gets older.

Stacy Brethauer, MD, will lead discussion on the influence of BMI on bariatric surgery, and the influence of obesity on public health.

Analysis of the Framingham Heart Study found that while quitting smoking lowers a person's CVD risk, that risk may not return to normal for up to 25 years.

Investigators from the University of Pennsylvania found that negative effects of vaping on blood vessels can be noted after a single use.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

Clinicians have indicated which symptom subtypes are associated with a greater risk of cardiovascular conditions in patients with OSA.

FDA announced the approval of lefamulin, which was based on the results of the LEAP 1 and LEAP 2 trials.